(August 12, 2020, 1:49 PM EDT) -- ALEXANDRIA, Va. — A claimed pharmaceutical composition for the treatment of hypertension, as embodied in the drug "Entresto," is unpatentable as obvious, a petitioner tells the Patent Trial and Appeal Board in an Aug. 7 request for inter partes review (IPR) (Biocon Pharma Limited v. Novartis Pharmaceuticals Corporation, No. IPR2020-01263, PTAB)....